

Mark T Ledwidge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1144778/publications.pdf>

Version: 2024-02-01

101
papers

4,234
citations

159585

30
h-index

114465

63
g-index

109
all docs

109
docs citations

109
times ranked

5730
citing authors

#	ARTICLE	IF	CITATIONS
1	Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 310, 66.	7.4	473
2	Diastolic Heart Failure. Circulation, 2007, 115, 888-895.	1.6	407
3	Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Human Molecular Genetics, 2014, 23, 2176-2188.	2.9	235
4	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 49, 753-762.	2.8	203
5	MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. European Journal of Heart Failure, 2015, 17, 405-415.	7.1	182
6	Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. European Journal of Heart Failure, 2011, 13, 1087-1095.	7.1	168
7	Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?. European Journal of Heart Failure, 2005, 7, 953-957.	7.1	150
8	Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization of medical care. Journal of Cardiac Failure, 2002, 8, 142-148.	1.7	139
9	The Biologic Variability of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Stable Heart Failure Patients. Journal of Cardiac Failure, 2007, 13, 50-55.	1.7	118
10	Natural History of Markers of Collagen Turnover in Patients With Early Diastolic Dysfunction and Impact of Eplerenone. Journal of the American College of Cardiology, 2009, 54, 1674-1682.	2.8	116
11	Exaggerated Inflammation and Monocytosis Associate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction: Evidence of M2 Macrophage Activation in Disease Pathogenesis. Journal of Cardiac Failure, 2015, 21, 167-177.	1.7	108
12	Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 2009, 11, 191-197.	7.1	107
13	Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzy. European Journal of Heart Failure, 2001, 3, 209-215.	7.1	81
14	Effects of surface active characteristics and solid state forms on the pH solubility profiles of drug-salt systems. International Journal of Pharmaceutics, 1998, 174, 187-200.	5.2	79
15	Nitric oxide-matrix metalloproteinase-9 interactions: Biological and pharmacological significance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 603-617.	4.1	79
16	Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 127-137.	2.0	76
17	Fluid Restriction in the Management of Decompensated Heart Failure: No Impact on Time to Clinical Stability. Journal of Cardiac Failure, 2007, 13, 128-132.	1.7	70
18	Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?. European Journal of Heart Failure, 2003, 5, 381-389.	7.1	68

#	ARTICLE	IF	CITATIONS
19	Proteomic Analysis of Coronary Sinus Serum Reveals Leucine-Rich Î±2-Glycoprotein as a Novel Biomarker of Ventricular Dysfunction and Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 188-197.	3.9	68
20	Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 267-272.	7.1	61
21	Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes. <i>Circulation: Heart Failure</i> , 2019, 12, e005765.	3.9	58
22	Decompensation of Chronic Heart Failure Associated With Pregabalin in Patients With Neuropathic Pain. <i>Journal of Cardiac Failure</i> , 2007, 13, 227-229.	1.7	53
23	Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-Î² mediated fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 9.	3.4	48
24	Costâ€ effectiveness of natriuretic peptideâ€ based screening and collaborative care: a report from the STOPâ€ HF (St Vincent's Screening TO Prevent Heart Failure) study. <i>European Journal of Heart Failure</i> , 2015, 17, 672-679.	7.1	42
25	Prospective Analysis of LDL-C Goal Achievement and Self-Reported Medication Adherence Among Statin Users in Primary Care. <i>Clinical Therapeutics</i> , 2011, 33, 1180-1189.	2.5	41
26	Modest Elevation in BNP in Asymptomatic Hypertensive Patients Reflects Sub-Clinical Cardiac Remodeling, Inflammation and Extracellular Matrix Changes. <i>PLoS ONE</i> , 2012, 7, e49259.	2.5	39
27	Quality of life predicts outcome in a heart failure disease management program. <i>International Journal of Cardiology</i> , 2010, 139, 60-67.	1.7	38
28	Long-Term Statin Therapy in Patients With Systolic Heart Failure and Normal Cholesterol: Effects on Elevated Serum Markers of Collagen Turnover, Inflammation, and B-Type Natriuretic Peptide. <i>Clinical Therapeutics</i> , 2012, 34, 91-100.	2.5	38
29	Are beta2â€ agonists responsible for increased mortality in heart failure?. <i>European Journal of Heart Failure</i> , 2011, 13, 885-891.	7.1	37
30	Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. <i>European Journal of Heart Failure</i> , 2004, 6, 235-243.	7.1	35
31	Nondipping Nocturnal Blood Pressure Predicts Sleep Apnea in Patients With Hypertension. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 957-963.	2.6	31
32	Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure?. <i>European Journal of Heart Failure</i> , 2013, 15, 447-455.	7.1	30
33	Physicochemical Characterization of Diclofenac N-(2-Hydroxyethyl)pyrrolidine: Anhydrate and Dihydrate Crystalline Forms. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 16-21.	3.3	29
34	Progression of preserved systolic function heart failure to systolic dysfunction â€” A natural history study. <i>International Journal of Cardiology</i> , 2006, 106, 95-102.	1.7	26
35	Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. <i>European Journal of Heart Failure</i> , 2005, 7, 385-391.	7.1	25
36	Attenuation of Monocyte Chemotaxisâ€”A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic Peptide. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 545-557.	2.4	23

#	ARTICLE	IF	CITATIONS
37	Atrial Tissue Pro-Fibrotic M2 Macrophage Marker CD163+, Gene Expression of Procollagen and B-Type Natriuretic Peptide. <i>Journal of the American Heart Association</i> , 2020, 9, e013416.	3.7	23
38	Heart Failure in Sub-Saharan Africa. <i>Cardiac Failure Review</i> , 2018, 4, 1.	3.0	23
39	A Central Role for Monocyte-Platelet Interactions in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 245-261.	2.0	22
40	Diabetes and complications of the heart in Sub-Saharan Africa: An urgent need for improved awareness, diagnostics and management. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 10-19.	2.8	22
41	Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose. <i>ESC Heart Failure</i> , 2020, 7, 159-167.	3.1	22
42	Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta. <i>Connective Tissue Research</i> , 2014, 55, 248-256.	2.3	21
43	Biomarker profiling for risk of future heart failure (HFpEF) development. <i>Journal of Translational Medicine</i> , 2021, 19, 61.	4.4	21
44	A Machine Learning Approach for Chronic Heart Failure Diagnosis. <i>Diagnostics</i> , 2021, 11, 1863.	2.6	21
45	A systematic review of clinical prediction rules for the diagnosis of chronic heart failure. <i>ESC Heart Failure</i> , 2019, 6, 499-508.	3.1	20
46	Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. <i>Journal of Cardiac Failure</i> , 2008, 14, 555-560.	1.7	19
47	Aspirin Use in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 243-250.	3.9	19
48	Heart Failure Virtual Consultation: bridging the gap of heart failure care in the community - A mixed methods evaluation. <i>ESC Heart Failure</i> , 2017, 4, 252-258.	3.1	19
49	Disease management programs for heart failure: Not just for the "sick" heart failure population. <i>European Journal of Heart Failure</i> , 2007, 9, 113-117.	7.1	18
50	The St Vincent's potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. <i>European Journal of Heart Failure</i> , 2014, 16, 915-922.	7.1	18
51	Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. <i>British Journal of Pharmacology</i> , 2012, 166, 938-949.	5.4	17
52	Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics. <i>Tropical Medicine and International Health</i> , 2015, 20, 581-588.	2.3	17
53	Life expectancy for community-based patients with heart failure from time of diagnosis. <i>International Journal of Cardiology</i> , 2015, 178, 268-274.	1.7	17
54	FKBP1 is associated with metabolic parameters and is a novel determinant of cardiovascular disease. <i>Scientific Reports</i> , 2020, 10, 21655.	3.3	17

#	ARTICLE	IF	CITATIONS
55	Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. <i>Scientific Reports</i> , 2020, 10, 7507.	3.3	17
56	Effects of environmental factors on the dehydration of diclofenac HEP dihydrate and theophylline monohydrate. <i>International Journal of Pharmaceutics</i> , 1997, 147, 41-49.	5.2	15
57	Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 480-486.	7.1	15
58	Intrauterine insemination—No more Mr. N.I.C.E. guy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 342-347.	1.1	15
59	Changing to remote management of a community heart failure population during COVID-19—Clinician and patient perspectives™. <i>IJC Heart and Vasculature</i> , 2020, 31, 100665.	1.1	14
60	Natriuretic Peptide-based Screening and Prevention of Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 83.	3.0	14
61	Heart failure management programs: Can we afford to ignore the inpatient phase of care?. <i>Journal of Cardiac Failure</i> , 2003, 9, 258-262.	1.7	13
62	Progression of left atrial volume index in a population at risk for heart failure: a substudy of the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 957-964.	7.1	13
63	Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. <i>European Journal of Heart Failure</i> , 2007, 9, 1196-1204.	7.1	12
64	Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. <i>Pharmacogenomics Journal</i> , 2022, 22, 89-99.	2.0	12
65	Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults. <i>Acta Haematologica</i> , 2017, 138, 223-232.	1.4	11
66	B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension. <i>American Journal of Hypertension</i> , 2018, 31, 228-234.	2.0	11
67	Specialist Nurse Supervised In-Hospital Titration to Target Dose ACE Inhibitor—Is It Safe and Feasible in a Community Heart Failure Population?. <i>European Journal of Cardiovascular Nursing</i> , 2003, 2, 183-188.	0.9	10
68	Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 64, 77-89.	2.4	8
69	Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 87.	1.7	8
70	B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's™) Tj ETQq0 0 0 rgB2.1.0verlock 10 Tf 50		
71	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. <i>The Cochrane Library</i> , 2019, 10, CD013015.	2.8	7
72	Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6495-6499.	3.6	7

#	ARTICLE	IF	CITATIONS
73	Multiplexed measurement of candidate blood protein biomarkers of heart failure. ESC Heart Failure, 2021, 8, 2248-2258.	3.1	7
74	Aetiology and severity of childhood pneumonia in primary care in Malawi: a cohort study. BMJ Open, 2021, 11, e046633.	1.9	7
75	Associates of an Elevated Natriuretic Peptide Level in Stable Heart Failure Patients: Implications for Targeted Management. Scientific World Journal, The, 2013, 2013, 1-10.	2.1	6
76	Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease. Journal of Cardiovascular Translational Research, 2015, 8, 554-566.	2.4	6
77	Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. Biomarkers, 2016, 21, 538-543.	1.9	6
78	The Heart Failure Virtual Consultationâ€™â€™â€™a powerful tool for the delivery of specialist care and the democratization of knowledge in the community. European Journal of Heart Failure, 2019, 21, 255-256.	7.1	6
79	NTâ€™roBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme. ESC Heart Failure, 2021, 8, 5081-5091.	3.1	6
80	Multidisciplinary Care of Heart Failure: What Have We Learned and Where Can We Improve?. European Journal of Cardiovascular Nursing, 2003, 2, 247-249.	0.9	5
81	The prehospital patient pathway and experience of care with acute heart failure: a comparison of two health care systems. ESC Heart Failure, 2021, 8, 1076-1084.	3.1	5
82	Developing a disease management program for the improvement of heart failure outcomes: the doâ€™ts and the donâ€™ts. Expert Review of Cardiovascular Therapy, 2019, 17, 267-273.	1.5	4
83	ECSIT is a critical limiting factor for cardiac function. JCI Insight, 2021, 6, .	5.0	4
84	Community Direct Access Service for Early Detection and Treatment of Clinical Deterioration. Disease Management and Health Outcomes, 2006, 14, 185-190.	0.4	3
85	Need and evolution of need for device therapy in a community heart failure population. European Journal of Heart Failure, 2008, 10, 601-607.	7.1	3
86	Clinical and psychological impact of prophylactic implantable cardioverter-defibrillators in a community heart failure population. Irish Journal of Medical Science, 2011, 180, 369-374.	1.5	3
87	In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. Atherosclerosis, 2012, 221, 478-483.	0.8	3
88	Role of Monitoring Devices in Preventing Heart Failure Admissions. Current Heart Failure Reports, 2015, 12, 269-275.	3.3	3
89	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. International Journal of Heart Failure, 2021, 3, 106.	2.7	3
90	Newâ€™onset heart failure in the STOPâ€™CHF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. European Journal of Heart Failure, 2020, 22, 378-380.	7.1	2

#	ARTICLE	IF	CITATIONS
91	A Systematic Review of Clinical Prediction Rules to Predict Hospitalisation in Children with Lower Respiratory Infection in Primary Care and their Validation in a New Cohort. <i>EClinicalMedicine</i> , 2021, 41, 101164.	7.1	2
92	Cardiovascular risk prediction“Are we missing something?. <i>European Journal of Heart Failure</i> , 2020, 22, 1291-1293.	7.1	1
93	Reassuring cardiac and non-cardiac outcomes for heart failure patients managed in a disease management programme during the COVID-19 pandemic. <i>IJC Heart and Vasculature</i> , 2022, 38, 100931.	1.1	1
94	Cardiac MRI e-prime predicts myocardial late gadolinium enhancement and diastolic dysfunction in hypertrophic cardiomyopathy. <i>European Journal of Radiology</i> , 2022, 149, 110192.	2.6	1
95	The authors respond:. <i>Clinical Therapeutics</i> , 2011, 33, 2090.	2.5	0
96	Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	0
97	LONGITUDINAL CHANGE IN SOLUBLE ST2 VERSUS B-TYPE NATRIURETIC PEPTIDE IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS IN THE COMMUNITY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1823.	2.8	0
98	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. <i>The Cochrane Library</i> , 0, , .	2.8	0
99	Reducing Heart Failure Risk in People With Diabetes: The STOP HF Midlands Project. <i>Journal of Cardiac Failure</i> , 2020, 26, 444-445.	1.7	0
100	426“..A systematic review of clinical prediction rules to diagnose bacterial lower respiratory infection in children in primary care and their validation in a new cohort. , 2021, , .		0
101	Implementing Innovative Approaches to Healthcare in a Lower-Middle Income Country: Perspectives from Malawi. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1723-1730.	1.8	0